Download PDF
Der Klinikarzt 2005; 34(7): 211-216
DOI: 10.1055/s-2005-872424
In diesem Monat

© Georg Thieme Verlag Stuttgart · New York

Feste Größe im Therapieplan - Radioonkologische Therapiekonzepte zur Behandlung des Bronchialkarzinoms

Constant Factor in Therapy - Radiotherapy in the Treatment of Lung CancerM.W. Münter[1] , K. Herfarth[1] , J. Debus[1]
  • 1Abteilung für Radioonkologie und Strahlentherapie, Radiologische Klinik, Universitätsklinikum Heidelberg (Ärztlicher Direktor: Prof. Dr. Dr. J. Debus)
Further Information

Publication History

Publication Date:
28 July 2005 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Die Radiotherapie hat in der meist multimodalen Behandlung des Bronchialkarzinoms einen festen Stellenwert. Beim nichtkleinzelligen Bronchialkarzinom (NSCLC) wird sie vor allem im inoperablen Stadium III A und im Stadium III B eingesetzt - bei Patienten im guten Allgemeinzustand in der Regel als simultane oder sequenzielle Radiochemotherapie. Die verbesserten Ergebnisse solcher kombinierter Therapieansätze gehen meist mit einer erhöhten therapiebedingten Toxizität einher. Postoperativ sollte eine Radiotherapie beim nichtkleinzelligen Bronchialkarzinom bei nicht kompletter Resektion (R1, R2) sowie pN2-Situation erfolgen. Zudem kann sie bei der lokalen Behandlung des Stadiums IV, in der Notfallbehandlung sowie bei der Behandlung von Hirnmetastasen des nichtkleinzelligen Bronchialkarzinoms das Überleben der Patienten verlängern sowie deren Lebensqualität verbessern. Bei der Behandlung des kleinzelligen Bronchialkarzinoms kommt die Radiotherapie vor allem im Stadium „limited disease” als Konsolidierung nach systemischer Chemotherapie zum Einsatz.

Summary

Radiotherapy has an essential significance in the multimodal treatment of non-small cell and small cell lung cancer. For non-small cell lung cancer (NSCLC) radiotherapy is mainly applied in inoperable Stage III A and Stage III B disease. According to current studies patients in good general conditions will receive a simultaneous or sequential radiochemotherapy. A simultaneous radiochemotherapy should be performed in protocols. The better outcome of a combined radiochemotherapy is associated with a higher acute toxicity. In the postoperative situation, patients with an incomplete resection (R1, R2) or pN2-situation should also receive radiotherapy. Furthermore, radiotherapy improves survival and quality of live for patients with non-small cell lung cancer in the treatment of stage IV disease, emergency situations and brain metastases. In the treatment of small cell lung cancer (SCLC) stage limited disease radiotherapy is performed after chemotherapy for consolidation of the primary tumor site.

Key Words

radiotherapy - lung cancer - review - non-small cell - small cell

Literatur

  • 1 Albain KS, Rusch VW, Crowley JJ. et al. . Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.  J Clin Oncol. 1995;  13 1880-1892
    CrossrefPubMedGoogle Scholar
  • 2 Andre F, Grunenwald D, Pujol JL. et al. . Patterns of relapse of N2 nonsmall-cell lung carcinoma patients treated with preoperative chemotherapy: should prophylactic cranial irradiation be reconsidered?.  Cancer. 2001;  91 2394-2400
    CrossrefPubMedGoogle Scholar
  • 3 Anonymous . Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials.  BMJ. 1995;  311 899-909
    Google Scholar
  • 4 PORT Meta-analysis Trialists Group. . Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials.  Lancet. 1998;  352 257-263
    CrossrefPubMedGoogle Scholar
  • 5 Arriagada R, le T Chevalier, Ruffie P. et al. . Alternating radiotherapy and chemotherapy in 173 consecutive patients with limited small cell lung carcinoma. GROP and the French Cancer Center's Lung Group.  Int J Radiat Oncol Biol Phys. 1990;  19 1135-1138
    PubMedGoogle Scholar
  • 6 Auperin A, Arriagada R, Pignon JP. et al. . Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group.  N Engl J Med. 1999;  341 476-484
    CrossrefPubMedGoogle Scholar
  • 7 Byhardt RW, Pajak TF, Emami B. et al. . A phase I/II study to evaluate accelerated fractionation via concomitant boost for squamous, adeno, and large cell carcinoma of the lung: report of Radiation Therapy Oncology Group 84-07.  Int J Radiat Oncol Biol Phys. 1993;  26 459-468
    PubMedGoogle Scholar
  • 8 Carmack E. Surgical treatment of small cell lung cancer.  Lung Cancer. 1994;  11 228
    CrossrefPubMedGoogle Scholar
  • 9 Choi NC, Carey RW, Daly W. et al. . Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer.  J Clin Oncol. 1997;  15 712-722
    PubMedGoogle Scholar
  • 10 Chung CK, Stryker JA, O'Neill Jr M. et al. . Evaluation of adjuvant postoperative radiotherapy for lung cancer.  Int J Radiat Oncol Biol Phys. 1982;  8 1877-1880
    PubMedGoogle Scholar
  • 11 Clamon G, Herndon J, Cooper R. et al. . Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group.  J Clin Oncol. 1999;  17 4-11
    PubMedGoogle Scholar
  • 12 Cox JD, Azarnia N, Byhardt RW. et al. . A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11.  J Clin Oncol. 1990;  8 1543-1555
    CrossrefPubMedGoogle Scholar
  • 13 Dillman RO, Herndon J, Seagren SL. et al. . Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.  J Natl Cancer Inst. 1996;  88 1210-1215
    CrossrefPubMedGoogle Scholar
  • 14 Dillman RO, Seagren SL, Propert KJ. et al. . A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer.  N Engl J Med. 1990;  323 940-945
    CrossrefPubMedGoogle Scholar
  • 15 Dosoretz DE, Galmarini D, Rubenstein JH. et al. . Local control in medically inoperable lung cancer: an analysis of its importance in outcome and factors determining the probability of tumor eradication.  Int J Radiat Oncol Biol Phys. 1993;  27 507-516
    CrossrefPubMedGoogle Scholar
  • 16 Eberhardt W, Wilke H, Stamatis G. et al. . Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial.  J Clin Oncol. 1998;  16 622-634
    PubMedGoogle Scholar
  • 17 Furuse K, Kawahara M, Nishiwaki Y. et al. . Phase I/II study of vinorelbine, mitomycin, and cisplatin for stage IIIB or IV non-small-cell lung cancer.  J Clin Oncol. 1999;  17 3195-3200
    PubMedGoogle Scholar
  • 18 Gregor A, Macbeth FR, Paul J. et al. . Radical radiotherapy and chemotherapy in localized inoperable non-small-cell lung cancer: a randomized trial.  J Natl Cancer Inst. 1993;  85 997-999
    PubMedGoogle Scholar
  • 19 Hilaris BS, Martini N, Wong GY. et al. . Treatment of superior sulcus tumor (Pancoast tumor).  Surg Clin North Am. 1987;  67 965-977
    PubMedGoogle Scholar
  • 20 Hof H, Herfarth KK, Munter M. et al. . Stereotactic single-dose radiotherapy of stage I non-small-cell lung cancer (NSCLC).  Int J Radiat Oncol Biol Phys. 2003;  56 335-341
    CrossrefPubMedGoogle Scholar
  • 21 Jeremic B, Shibamoto Y, Nikolic N. et al. . Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study.  J Clin Oncol. 1999;  17 2092-2099
    PubMedGoogle Scholar
  • 22 Kaskowitz L, Graham MV, Emami B. et al. . Radiation therapy alone for stage I non-small cell lung cancer.  Int J Radiat Oncol Biol Phys. 1993;  27 517-523
    CrossrefPubMedGoogle Scholar
  • 23 Kent MS, Bilsky MH, Rusch VW. Resection of superior sulcus tumors (posterior approach).  Thorac Surg Clin. 2004;  14 217-228
    CrossrefPubMedGoogle Scholar
  • 24 Komaki R, Mountain CF, Holbert JM. et al. . Superior sulcus tumors: treatment selection and results for 85 patients without metastasis (Mo) at presentation.  Int J Radiat Oncol Biol Phys. 1990;  19 31-36
    PubMedGoogle Scholar
  • 25 Kristjansen PE, Kristensen CA. The role of prophylactic cranial irradiation in the management of small cell lung cancer.  Cancer Treat Rev. 1993;  19 3-16
    PubMedGoogle Scholar
  • 26 Le Chevalier T, Arriagada R, Quoix E. et al. . Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients.  J Natl Cancer Inst. 1991;  83 417-423
    CrossrefPubMedGoogle Scholar
  • 27 Le Chevalier T, Lynch T. Adjuvant treatment of lung cancer: current status and potential applications of new regimens.  Lung Cancer. 2004;  46 S33-S39
    PubMedGoogle Scholar
  • 28 Livingston RB, Schulman S, Mira JG. et al. . Combined alkylators and multiple-site irradiation for extensive small cell lung cancer: a Southwest Oncology Group Study.  Cancer Treat Rep. 1986;  70 1395-1401
    PubMedGoogle Scholar
  • 29 Maggi G, Casadio C, Pischedda F. et al. . Combined radiosurgical treatment of pancoast tumor.  Ann Thorac Surg. 1994;  57 198-202
    CrossrefPubMedGoogle Scholar
  • 30 Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis.  Cancer. 1995;  76 593-601
    CrossrefPubMedGoogle Scholar
  • 31 Millar J, Ball D, Worotniuk V. et al. . Radiation treatment of superior sulcus lung carcinoma.  Australas Radiol. 1996;  40 55-60
    PubMedGoogle Scholar
  • 32 Payne DG. Non-small-cell lung cancer: should unresectable stage III patients routinely receive high-dose radiation therapy?.  J Clin Oncol. 1988;  6 552-558
    PubMedGoogle Scholar
  • 33 Perez CA, Stanley K, Rubin P. et al. . A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group.  Cancer. 1980;  45 2744-2753
    CrossrefPubMedGoogle Scholar
  • 34 Perez CA, Stanley K, Rubin P. et al. . Patterns of tumor recurrence after definitive irradiation for inoperable non-oat cell carcinoma of the lung.  Int J Radiat Oncol Biol Phys. 1980;  6 987-994
    PubMedGoogle Scholar
  • 35 Pignon JP, Arriagada R, Ihde DC. et al. . A meta-analysis of thoracic radiotherapy for small-cell lung cancer.  N Engl J Med. 1992;  327 1618-1624
    CrossrefPubMedGoogle Scholar
  • 36 Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis.  Ann Intern Med. 1996;  125 723-729
    PubMedGoogle Scholar
  • 37 Rosenthal SA, Curran Jr WJ, Herbert SH. et al. . Clinical stage II non-small cell lung cancer treated with radiation therapy alone. The significance of clinically staged ipsilateral hilar adenopathy (N1 disease).  Cancer. 1992;  70 2410-2417
    PubMedGoogle Scholar
  • 38 Sandler HM, Curran Jr WJ, Turrisi 3rd. AT. The influence of tumor size and pre-treatment staging on outcome following radiation therapy alone for stage I non-small cell lung cancer.  Int J Radiat Oncol Biol Phys. 1990;  19 9-13
    PubMedGoogle Scholar
  • 39 Saunders M, Dische S, Barrett A. et al. . Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee.  Radiother Oncol. 1999;  52 137-148
    CrossrefPubMedGoogle Scholar
  • 40 Schaake-Koning C, van den Bogaert W, Dalesio O. et al. . Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer.  N Engl J Med. 1992;  326 524-530
    PubMedGoogle Scholar
  • 41 Schraube P, Latz D. [The value of radiotherapy in the treatment of pancoast tumor of the lung].  Strahlenther Onkol. 1993;  169 265-269
    PubMedGoogle Scholar
  • 42 Schraube P, von Kampen M, Oetzel D. et al. . The impact of 3-D radiotherapy planning after a pneumonectomy compared to a conventional treatment set-up.  Radiother Oncol. 1995;  37 65-70
    CrossrefPubMedGoogle Scholar
  • 43 Trodella L, Granone P, Valente S. et al. . Adjuvant radiotherapy in non-small cell lung cancer with pathological stage I: definitive results of a phase III randomized trial.  Radiother Oncol. 2002;  62 11-19
    CrossrefPubMedGoogle Scholar
  • 44 Turrisi 3rd. AT. Incorporation of radiotherapy fractionation in the combined-modality treatment of limited small-cell lung cancer.  Chest. 1993;  103 418S-422S
    PubMedGoogle Scholar
  • 45 Turrisi 3rd. AT. Integrating thoracic radiotherapy in the treatment of limited small-cell lung cancer.  Oncology (Huntingt). 1998;  12 15-18
    PubMedGoogle Scholar
  • 46 Turrisi 3rd AT, Kim K, Blum R. et al. . Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.  N Engl J Med. 1999;  340 265-271
    CrossrefPubMedGoogle Scholar
  • 47 Turrisi 3rd AT. Prophylactic cranial irradiation in small-cell lung cancer: is it still controversial or is it a no-brainer?.  Oncologist. 2000;  5 299-301
    CrossrefPubMedGoogle Scholar
  • 48 Van Houtte P, MacLennan I, Poulter C. et al. . External radiation in the management of superior sulcus tumor.  Cancer. 1984;  54 223-227
    PubMedGoogle Scholar
  • 49 Willner J, Baier K, Caragiani E. et al. . Dose, volume, and tumor control prediction in primary radiotherapy of non-small-cell lung cancer.  Int J Radiat Oncol Biol Phys. 2002;  52 382-389
    CrossrefPubMedGoogle Scholar

1 postoperative radiotherapy in non-small-cell lung cancer

2 international adjuvant lung cancer trial

3 continous hyperfractionated accelerated radiotherapy

4 european organisation for research and treatment of cancer

5 cancer and leukemia group B

Anschrift für die Verfasser

Dr. Marc W. Münter

Klinik für Radioonkologie und Strahlentherapie, Universität Heidelberg

Im Neuenheimer Feld 400

69120 Heidelberg

      >